Roche RHHBY announced positive top-line results from a late-study on influenza drug, Xofluza.The CENTERSTONE study was a global phase III trial investigating the efficacy of single-dose Xofluza, taken...
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END
Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below.PFE...
/CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus...
Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...
Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...
After underperforming over the past few years, these stocks offer huge dividend yields that could keep rising throughout your retirement.
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...